Association of MDM2 Polymorphism with Risk and Prognosis of Leukemia: A Meta-Analysis | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Association of MDM2 Polymorphism with Risk and Prognosis of Leukemia: A Meta-Analysis

Acta Haematol (2015) 133 (4): 365–371.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study

Florin Tripon
Mihaela Iancu
Adrian Trifa
George Andrei Crauciuc
Alina Boglis
Beata Balla
Adriana Cosma
Delia Dima
Marcela Candea
Erzsebet Lazar
Laura Jimbu
Claudia Banescu

Journal of Clinical Medicine (2020) 9 (6): 1672.

Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study

Rostam Maruei‐Milan
Zahra Heidari
Saeedeh Salimi

Journal of Cellular Physiology (2019) 234 (8): 12934.

Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma

Adam S. Kibel
Jiyoung Ahn
Masis Isikbay
Aleksandra Klim
William S. Wu
Richard B. Hayes
William B. Isaacs
E. Warwick Daw

The Prostate (2016) 76 (5): 479.

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes

Kathy L. McGraw
Thomas Cluzeau
David A. Sallman
Ashley A. Basiorka
Brittany A. Irvine
Ling Zhang
P.K. Epling-Burnette
Dana E. Rollison
Mar Mallo
Lubomir Sokol
Francesc Solé
Jaroslaw Maciejewski
Alan F. List

Oncotarget (2015) 6 (33): 34437.